Table 1. Clinical trial design.
| Characteristics | Number of patients |
|---|---|
| Patients evaluable for response | 28 |
| Patients evaluable for toxicity | 29 |
| Sex | |
| Male | 20 |
| Female | 9 |
| Performance status (ECOG) | 0–2 |
| Primary site | |
| Sigma and left colon | 21 |
| Right colon | 8 |
| Stage IV | 29 (100%) |
| Disease extension | |
| (A) Liver | 24 |
| (B) No liver (bone+lung+peritoneum+ovary) | 5 |
| Previous treatments | |
| Surgery | 27 |
| One line of chemotherapy | 20 |
| Two or more lines of chemotherapy | 9 |
| FUFA | 23 |
| IFL | 7 |
| FOLFOX-4 | 3 |
| Raltitrexed | 1 |
| Intra-hepatic mytomicin C infusion | 3 |
The median age of the patients was 67.7 year (range 42–77).